Pneumocystis jirovecii pneumonia secondary to biological therapy with adalimumab
Neumonía por Penumocystis jirovecii secundaria al uso de terapia biológica con adalimumab
Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.
Show authors biography
Tumor necrosis factor-alpha (TNF-α) inhibitors offer a strategic therapeutic target in stark contrast with traditional immunosuppressant agents used in the treatment of multiple inflammatory diseases. These biological agents have a high impact on the reduction of signs and symptoms, as well as on the functional recovery of a great variety of diseases of autoimmune etiology. It has been determined, on the basis of data from epidemiological and clinical studies, that there is an increased susceptibility to infections secondary to inhibition of the production of different cytokines; a great variety of infections, especially of the granulomatous and fungal types, have been reported with the use of TNF-α. We report a case of P. jiroveci pneumonia in a female patient who received treatment with adalimumab.
Article visits 456 | PDF visits 290
Downloads
- Maury E, Hochberg M, Cassell S et al. Rheumatoid arthritis patients on TNF blockers have higher rates of infections. Arthritis and Rheumatism. 2005; 52 (supplement): S547eS548 [abstract].
- Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis and Rheumatism. 2005; 52: 3403e3412.
- Pifer LL, Hughes WT, Stagno S, Woods D. Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics 1978; 61: 35-41.
- Dohn MN, White ML, Vigdorth EM, Ralph Buncher C, Hertzberg VS, Baughman RP, et al. Geographic clustering of Pneumocystis carinii pneumonia in patients with HIV infection. Am J Respir Crit Care Med. 2000; 162: 1617-21.
- Kaur N, Mahl TC. Pneumocystis carinii pneumonia with oral candidiasis after infliximab therapy for Crohn’s disease. Digestive Diseases and Sciences 2004; 49: 1458e1460. 2:1481-4.
- Minee RC, Stokkers P, Riemens SC & Hommes DW. Pneumocystis pneumonia during infliximab for active Crohn’s colitis. Nederlands Tijdschrift Voor Geneeskunde. 2005; 149: 2290e2295.
- Velayos FS, Sandborn WJ. Pneumocystis carinii pneumonia during maintenance anti-tumor necrosisfactor-alpha therapy with infliximab for Crohn’s disease. Inflammatory Bowel Diseases. 2004; 10:657e660.
- Tai TL, O’Rourke KP, McWeeney M et al. Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology (Oxford). 2002; 41: 951e952.
- Ljung T, Karlen P, Schmidt D et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004; 53: 849e853.
- FDA Arthritis Advisory Committee Meeting. Fecha de acceso: June 2001. Disponible en: www.fda.gov/ohrms/dockets/ac/01/briefing/3779b2.htm;.
- Kolls JK, Lei D, Vazquez C, Odom G, Summer WR, Nelson S, et al. Exacerbation of murine Pneumocystis carinii infection by adenoviral-mediated gene transfer of a TNF inhibitor. Am J Respir Cell Mol Biol. 1997; 16: 112-8.
- Kaur N, Mahl TC. Pneumocystis jirovecii (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci. 2007; 5-75.
Information
Journal history
Keywords
QR code
Funding
Directories and indexes
